Apimeds Pharmaceuticals US, Inc.

$1.88 ▲ 7.43%
2026-04-21 05:21:01

Explore Apimeds Pharmaceuticals US, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.

Market Cap
$23.64 M
Current Price
$1.88
52W High / Low
$40.31 / $1.61
Stock P/E
Book Value
$0.65
Dividend Yield
ROCE
126.09%
ROE
209.61%
Face Value
EPS
$-0.41
Exp Qtr EPS
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
Beta
Debt / Equity
-0.44
Current Ratio
0.01
Quick Ratio
0.01
Forward P/E
Price / Sales
Enterprise Value
EV / EBITDA
EV / Revenue
Rating
None
Target Price
EPS Forecast (FY)

Pros

  • Healthy return on equity.
  • Efficient use of capital employed.
  • Balance sheet leverage appears manageable.

Cons

  • Current ratio suggests tighter short-term liquidity.
  • Operating margin is thin.
  • Net margin is relatively low.

Sift Stocks

S.No. Name Price P.E. Market Cap Div Yld % ROCE ROE 52Week High/ Low Book Value
1. Gelteq Limited $0.7 $7.5 M -31.25% -42.99% $4.11 / $0.64 $1.09
2. Talphera, Inc. $0.78 $40.17 M -52.04% -1.15% $1.57 / $0.38 $0.34
3. SCYNEXIS, Inc. $1.07 $47.85 M -30.16% -16.48% $1.31 / $0.56 $1.13
4. Canopy Growth Corporation $1.2 $709.79 M -8.06% -48.5% $3.28 / $1.18 $1.49
5. BGM Group Ltd. $0.36 $59.42 M -0.81% -3.37% $17.17 / $0.27 $1.85
6. Lantheus Holdings, Inc. $83.97 23.41 $5.47 B 16.66% 21.45% $108.91 / $47.25 $16.87
7. ANI Pharmaceuticals, Inc. $81.73 23.13 $1.81 B 0.06% 6.99% 16.16% $99.5 / $56.71 $25.8

Quarterly Results

Figures shown in M / B

Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Sales0 M0 M0 M0 M0 M
Operating Profit-1.84 M-2.66 M-0.36 M-0.28 M-0.3 M
Net Profit-1.78 M-2.66 M-0.4 M-0.31 M-0.33 M
EPS in Rs-1.42-2.12-0.32-0.25-0.26

Profit & Loss

Figures shown in M / B

2024202320222021
Sales0 M0 M0 M0 M
Operating Profit-1.28 M-0.75 M-0.64 M-1.02 M
Net Profit-1.39 M-0.78 M-0.67 M-1.03 M
EPS in Rs-1.11-0.62-0.53-0.82

Balance Sheet

Figures shown in M / B

2024202320222021
Total Assets0.01 M0.42 M0.01 M0.17 M
Total Liabilities1.37 M0.39 M0.72 M0.41 M
Equity-1.36 M0.03 M-0.71 M-0.24 M
Current Assets0.01 M0.42 M0.01 M0.17 M
Current Liabilities1.02 M0.12 M0.32 M0.01 M

Cash Flow

Last available yearly cash flow history

2024202320222021
Operating CF-0.73 M-0.63 M-0.45 M-0.82 M
Investing CF0 M0 M0 M0 M
Financing CF0.33 M1.03 M0.28 M0.4 M
Free CF-0.73 M-0.63 M-0.45 M-0.82 M
Capex

5Y Margin & Growth History

Last 5 year derived history from yfinance annual statements

2024202320222021
Revenue Growth %
Earnings Growth %-78.73%-16.31%34.84%
Profit Margin %
Operating Margin %
Gross Margin %
EBITDA Margin %

Dividend & Split History

Latest dividend and stock split events stored from yfinance

Dividend History

No dividend history available.

Stock Splits

DateSplit
2026-03-261:0.1

Shareholding Pattern

Shares and value shown in M / B

Holder Name Type Shares Value % Out Report Date
Fidelity Concord Street Trust-Fidelity Extended Market Index Fund Mutual Fund 0.02 M $0.04 M 0% 2026-01-31
Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund Mutual Fund 0.01 M $0.02 M 0% 2026-01-31
Hemenway Trust Company LLC Institutional 0.27 M $0.52 M 0.02% 2025-12-31
Vanguard Group Inc Institutional 0.06 M $0.11 M 0% 2025-12-31
Geode Capital Management, LLC Institutional 0.03 M $0.07 M 0% 2025-12-31
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund Mutual Fund 0.03 M $0.07 M 0% 2025-12-31
Jane Street Group, LLC Institutional 0.03 M $0.05 M 0% 2025-12-31
UBS Group AG Institutional 0 M $0 M 2025-12-31
Bank of America Corporation Institutional 0 M $0 M 2025-12-31
Tower Research Capital LLC (TRC) Institutional 0 M $0 M 2025-12-31